CureVac N.V. (CVAC)

2.3300 +0.0200 (+0.87%) At close: 04:00PM EDT

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Alexander Zehnder M.B.A., M.D.	CEO, MD & Member of Management Board	1.05M	N/A	1970
Mr. Pierre Kemula B.Sc.	MD, CFO & Member of Management Board	699.9k	N/A	1975
Dr. Malte Greune Ph.D.	COO, Member of Management Board & MD	642.73k	N/A	1965
Dr. Myriam Mendila M.D.	Chief Development Officer, MD & Member of the Management Board	657.44k	N/A	1966
Dr. Ulrike Gnad-Vogt M.D., Ph.D.	Senior VP & Area Head of Oncology	304.01k	N/A	1973
Dr. Sarah Fakih	Vice President Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Marco Rau L.L.M., Ph.D.	General Counsel	N/A	N/A	N/A
Mr. Thorsten Schuller	Head of Corporate Communications	N/A	N/A	N/A
Slavica Stevanovic-Heck	Head of Human Resources	N/A	N/A	N/A
Dr. Patrick Baumhof	Senior Vice President of Technology	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate governance

CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.